Related references
Note: Only part of the references are listed.Inhibition of Bcl-2 improves effect of LCL161, a SMAC mimetic, in hepatocellular carcinoma cells
Kuen-Feng Chen et al.
BIOCHEMICAL PHARMACOLOGY (2012)
Induction of cell proliferation and survival genes by estradiol-repressed microRNAs in breast cancer cells
Xinfeng Yu et al.
BMC CANCER (2012)
A phase I trial of pan-Bcl-2 antagonist obatoclax administered as a 3-h or a 24-h infusion in combination with carboplatin and etoposide in patients with extensive-stage small cell lung cancer
A. A. Chiappori et al.
BRITISH JOURNAL OF CANCER (2012)
Cancer Statistics, 2012
Rebecca Siegel et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2012)
MiR-136 promotes apoptosis of glioma cells by targeting AEG-1 and Bcl-2
Yi Yang et al.
FEBS LETTERS (2012)
Etoposide induces a mixed type of programmed cell death and overcomes the resistance conferred by Bcl-2 in Hep3B hepatoma cells
Seung Hee Yoo et al.
INTERNATIONAL JOURNAL OF ONCOLOGY (2012)
MiR-181d acts as a tumor suppressor in glioma by targeting K-ras and Bcl-2
Xie-Feng Wang et al.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2012)
Substantial Susceptibility of Chronic Lymphocytic Leukemia to BCL2 Inhibition: Results of a Phase I Study of Navitoclax in Patients With Relapsed or Refractory Disease
Andrew W. Roberts et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Signaling Networks Associated with AKT Activation in Non-Small Cell Lung Cancer (NSCLC): New Insights on the Role of Phosphatydil-Inositol-3 kinase
Marianna Scrima et al.
PLOS ONE (2012)
MET-Independent Lung Cancer Cells Evading EGFR Kinase Inhibitors Are Therapeutically Susceptible to BH3 Mimetic Agents
Weiwen Fan et al.
CANCER RESEARCH (2011)
Phase I Study of Navitoclax (ABT-263), a Novel Bcl-2 Family Inhibitor, in Patients With Small-Cell Lung Cancer and Other Solid Tumors
Leena Gandhi et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Overexpression of MUC1 Enhances Proangiogenic Activity of Non-Small-Cell Lung Cancer Cells Through Activation of Akt and Extracellular Signal-regulated Kinase Pathways
Mengying Yao et al.
LUNG (2011)
被撤回的出版物: Antitumor activity of bortezomib in human cancer cells with acquired resistance to anti-epidermal growth factor receptor tyrosine kinase inhibitors (Retracted article. See vol. 181, 2023)
Floriana Morgillo et al.
LUNG CANCER (2011)
Induction of Bcl-2 Expression by Hepatitis B Virus Pre-S2 Mutant Large Surface Protein Resistance to 5-Fluorouracil Treatment in Huh-7 Cells
Jui-Hsiang Hung et al.
PLOS ONE (2011)
Bcl-2 and β1-integrin predict survival in a tissue microarray of small cell lung cancer
M. H. Lawson et al.
BRITISH JOURNAL OF CANCER (2010)
Compensatory activation of Akt in response to mTOR and Raf inhibitors - A rationale for dual-targeted therapy approaches in neuroendocrine tumor disease
Kathrin Zitzmann et al.
CANCER LETTERS (2010)
Targeting Apoptotic Signaling Pathways in Human Lung Cancer
S. W. Han et al.
CURRENT CANCER DRUG TARGETS (2010)
Phase II Trial of Gefitinib and Everolimus in Advanced Non-small Cell Lung Cancer
Katharine A. Price et al.
JOURNAL OF THORACIC ONCOLOGY (2010)
The Combination of Multiple Receptor Tyrosine Kinase Inhibitor and Mammalian Target of Rapamycin Inhibitor Overcomes Erlotinib Resistance in Lung Cancer Cell Lines through c-Met Inhibition
Ichiro Nakachi et al.
MOLECULAR CANCER RESEARCH (2010)
PTEN Loss Contributes to Erlotinib Resistance in EGFR-Mutant Lung Cancer by Activation of Akt and EGFR
Martin L. Sos et al.
CANCER RESEARCH (2009)
Combination of taxol and Bcl-2 siRNA induces apoptosis in human glioblastoma cells and inhibits invasion, angiogenesis and tumour growth
Joseph George et al.
JOURNAL OF CELLULAR AND MOLECULAR MEDICINE (2009)
Clinical Features and Outcome of Patients With Non-Small-Cell Lung Cancer Who Harbor EML4-ALK
Alice T. Shaw et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
A Phase I Study of the Pan Bcl-2 Family Inhibitor Obatoclax Mesylate in Patients with Advanced Hematologic Malignancies
Aaron D. Schimmer et al.
CLINICAL CANCER RESEARCH (2008)
First-line gefitinib in patients with advanced non-small-cell lung cancer harboring somatic EGFR mutations
Lecia V. Sequist et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Targeting the apoptotic pathway with BCL-2 inhibitors sensitizes primary chronic lymphocytic leukemia cells to vesicular stomatitis virus-induced oncolysis
Vanessa Fonseca Tumilasci et al.
JOURNAL OF VIROLOGY (2008)
Efficacy of everolimus in advanced renal cell carcinoma:: a double-blind, randomised, placebo-controlled phase III trial
Robert J. Motzer et al.
LANCET (2008)
BIM mediates EGFR tyrosine kinase inhibitor-induced apoptosis in lung cancers with oncogenic EGFR mutations
Daniel B. Costa et al.
PLOS MEDICINE (2007)
Bcl-2 downregulation sensitizes nonsmall cell lung cancer cells to cisplatin, but not to docetaxel
Doris Losert et al.
ANTI-CANCER DRUGS (2007)
MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling
Jeffrey A. Engelman et al.
SCIENCE (2007)
Activation of downstream epidermal growth factor receptor (EGFR) signaling provides gefitinib-resistance in cells carrying EGFR mutation
Akiko Uchida et al.
CANCER SCIENCE (2007)
Phosphorylated Akt overexpression and loss of PTEN expression in non-small cell lung cancer confers poor prognosis
JM Tang et al.
LUNG CANCER (2006)
Restoring E-cadherin expression increases sensitivity to epidermal growth factor receptor inhibitors in lung cancer cell lines
SE Witta et al.
CANCER RESEARCH (2006)
Enhanced cytotoxicity induced by gefitinib and specific inhibitors of the Ras or phosphatidyl inositol-3 kinase pathways in non-small cell lung cancer cells
ML Janmaat et al.
INTERNATIONAL JOURNAL OF CANCER (2006)
Epithelial membrane protein-1 is a biomarker of gefitinib resistance
A Jain et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2005)
Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain
W Pao et al.
PLOS MEDICINE (2005)
EGFR mutation and resistance of non-small-cell lung cancer to gefitinib
S Kobayashi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Specific downregulation of bcl-2 and xIAP by RNAi enhances the effects of chemotherapeutic agents in MCF-7 human breast cancer cells
RT Lima et al.
CANCER GENE THERAPY (2004)
EGF receptor gene mutations are common in lung cancers from never smokers and are associated with sensitivity of tumors to gefitinib and erlotinib
W Pao et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2004)
Gefitinib induces apoptosis in the EGFRL858R non-small-cell lung cancer cell line H3255
S Tracy et al.
CANCER RESEARCH (2004)
Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib
TJ Lynch et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Reduced expression of p27 is a novel mechanism of docetaxel resistance in breast cancer cells
I Brown et al.
BREAST CANCER RESEARCH (2004)
Loss of PTEN/MMAC1/TEP in EGF receptor-expressing tumor cells counteracts the antitumor action of EGFR tyrosine kinase inhibitors
R Bianco et al.
ONCOGENE (2003)
RNA interference may be more potent than antisense RNA in human cancer cell lines
Y Aoki et al.
CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY (2003)
Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor types
J Baselga et al.
JOURNAL OF CLINICAL ONCOLOGY (2002)
Share Paper
